Dr. Pallawi Torka of Memorial Sloan Kettering Cancer Center joins to share highlights from ASCO and EHA 2025 on the evolving landscape of B-cell lymphomas, including Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma. She offers in-depth insights on the STARGLO study and its recent ODAC review, the POLARGO trial, a rare T-cell leukemia (T-LGL) study, and new data supporting nivolumab-AVD in frontline Hodgkin lymphoma. Additional discussion includes the inMIND trial for follicular lymphoma, the growing role of ctDNA in managing DLBCL, advances in CAR-T cell therapy for CNS lymphoma, and how she is adapting treatment strategies based on favorable vs. unfavorable disease features.

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Dr. Ben Derman of the University of Chicago Medicine joins the show to unpack major updates in multiple myeloma presented at ASCO and EHA 2025. He discusses the growing role of quadruple therapy across all patient populations and its implications for the future of autologous stem cell transplant, including insights from the MIDAS trial on MRD-guided transplant decisions. Additional highlights include MRD-negativity as a potential off-ramp for maintenance therapy, evolving data from frontline triplet vs. quadruplet studies, real-world referral trends, CARTITUDE-4 subgroup outcomes, and the expanding utility of bispecifics and trispecific antibodies, particularly for extramedullary disease.

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Joe DePinto, MBA, Head of Cell, Gene & Advanced Therapies at McKesson, joins the show to discuss InspiroGene, McKesson’s end-to-end platform built to address the complex delivery, coordination, and commercialization needs of cell and gene therapies. He breaks down how InspiroGene integrates logistics, specialty pharmacy, patient support services, and real-time data tracking to close critical gaps in the CGT ecosystem—especially around why many eligible patients are still not being identified, referred, or treated. He also explores the broader vision: enabling scalable access to these therapies as they move from rare diseases to larger populations, and what it will take—from providers, payers, and pharma—to meet that future.

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Chadi sits down with Lou Weisbach, entrepreneur and founder of the American Center for Cures, who shares his ambitious mission to raise $750 billion through an innovative public-private bond model to accelerate the prevention and cure of chronic diseases like cancer, Alzheimer's, diabetes, and Parkinson’s. Weisbach discusses how his model is designed to align incentives across government, industry, and research institutions, bridging political divides and pharmaceutical interests to focus on cure-based rather than treatment-based outcomes. He also reflects on two decades of groundwork, key milestones achieved, and how the initiative operates day-to-day, including the development of disease-specific platforms poised to transform biomedical research and public health.

Find out more about his cause.

https://theamericancenterforcures.org/

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Dr. Vivek Subbiah returns for another edition of Vivek’s Takes, offering his expert insights on the standout science from the 2025 ASCO Annual Meeting. He breaks down key developments including trispecific antibodies, the growing role of radioligand therapies, a new standard of care in small cell lung cancer, and paradigm-shifting data in adjuvant therapy for colorectal cancer. The discussion also highlights a long-term exercise intervention, adjuvant vaccine studies, ctDNA and MRD integration, resistance mechanisms, artificial intelligence, and other emerging trends shaping the future of oncology.

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Dena Marrinucci, PhD, co-founder and COO of Truvian Health, joins the show to discuss her mission to transform blood diagnostics through a point-of-care device that delivers rapid, actionable results. She shares the origin story of founding Truvian in 2015—coincidentally just weeks before the Theranos exposé—and reflects on navigating industry skepticism in the post-Theranos landscape. Marrinucci also outlines the company’s FDA submission process, the importance of empowering immediate patient-provider decision-making, and what the initial panel of 30+ lab tests offers for routine care, among so much more.

Read the article on the Truvian Health blood test.

https://www.newsweek.com/truvian-lab-company-blood-test-device-theranos-health-care-1997422

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Former FDA Commissioner Robert Califf returns to the show for an in-depth discussion on the integration of artificial intelligence into regulatory processes, including how AI is currently being used—and should be used—in drug and medical device approvals, the detection and review of fraudulent data, and clinical decision support systems. He also explores the boundaries between algorithmic automation and human judgment, emphasizing the importance of maintaining transparency, accountability, and trust in an increasingly data-driven regulatory landscape.

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Last week, Chadi and researchers explored the KETO-CTA study, which investigated the effects of the ketogenic diet on coronary plaque formation in Lean Mass Hyper-Responders (LMHR), or individuals who experience significant LDL cholesterol elevations on low-carb diets.

This week, the other side of the conversation is presented.

A leading cardiologist joins the show to critically examine the KETO-CTA study findings, questioning their clinical significance and broader applicability. What do these results really mean for cardiovascular risk in the general population? Should elevated LDL in the context of good metabolic health be treated the same as traditional hyperlipidemia?

This episode dives into the nuances of lipidology, the role of LDL in atherosclerosis, and the complexity of applying study findings to real-world patients.

Whether you're a clinician, researcher, or just interested in the science behind diet and heart health, this conversation is essential listening.

View the KETO-CTA study.

https://www.sciencedirect.com/science/article/pii/S2772963X25001036

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

The ketogenic (keto) diet has surged in popularity, with many touting its weight loss and metabolic benefits. However, some individuals—particularly those following a low-carb, high-fat regimen—experience a significant rise in LDL cholesterol, a phenomenon now known as the Lean Mass Hyper-Responder (LMHR) phenotype. What does this mean for cardiovascular risk?

In this episode, Chadi is joined by three of the lead investigators of the KETO-CTA study, recently published in The American Journal of Clinical Nutrition. They break down their findings on how the keto diet affects coronary plaque formation and what it could mean for LMHR individuals.

This is Part 1 of a two-part series. Next week, Chadi brings in a contrasting perspective on the study’s conclusions.

A must-listen series for anyone interested in the intersection of diet, cholesterol, and cardiovascular health.

View the KETO-CTA study.

https://www.sciencedirect.com/science/article/pii/S2772963X25001036

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Cardiologists Andrew Foy and Anish Koka return to the show for a deep and often contentious debate on one of the most pressing healthcare policy issues of our time: should the government negotiate drug prices? Using the Inflation Reduction Act (IRA) as a springboard, the conversation explores the underlying causes of inflated drug prices in the US, including the role of third-party payers, lack of transparency, and market distortions. The discussion also examines the global landscape—how other countries manage drug pricing—and whether those models offer lessons or cautionary tales. What impact will the IRA have on patients, access, and innovation? Can payers do more to control costs without sacrificing care? This episode dives into the complexities of healthcare economics, the free market, and the question of whether government intervention helps or hinders progress.

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA